Top 5 Small-cap Biotech Stocks in 2026

1. Cue Biopharma (NASDAQ:CUE)

Year-to-date gain: 293.6 percent
Market cap: US$477.18 million
Share price: US$36.51

Cue Biopharma makes engineered protein drugs that are designed to selectively activate or modulate specific T cells, rather than affecting the whole immune system. Its platform is built around Immuno-STAT biology, and in 2026 the company said CUE-401 is its main focus for autoimmune and inflammatory disease.

Cue has accelerated its clinical pipeline under newly appointed CEO Dr. Shao-Lee Lin. The company successfully executed a one-for-30 reverse stock split in late April, licensed a dual-mechanism allergy drug, CUE-221, and secured a US$50 million private placement financing in early July to extend its capital runway.

With the appointment of Dr. Dominic Borie as Cue's new chief medical officer and R&D head, the firm believes it is well positioned ahead of key data readouts expected by the end of Q3.

2. Q32 Bio (NASDAQ:QTTB)

Year-to-date gain: 281.52 percent
Market cap: US$153.35 million
Share price: US$12.59

Q32 Bio is an autoimmune and inflammation biotech company focused on rebalancing the immune system instead of suppressing it broadly. Its lead drug, bempikibart, is an antibody against IL-7R alpha, which is meant to dial down the overactive immune signaling that drives diseases like alopecia areata.

Q32 Bio announced a US$55 million private placement financing in late May, allowing it to completely wipe out its remaining bank debt. This financial stability set the stage for a clinical milestone in July, when the company announced successful Phase 2a data for bempikibart. The breakthrough data triggered an immediate share price surge, and soon after the company announced pricing for a US$200 million common stock offering.

3. Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Year-to-date gain: 270.08 percent
Market cap: US$334.58 million
Share price: US$4.70

Zentalis Pharmaceuticals is an oncology drug company focused on an oral WEE1 inhibitor called azenosertib, which makes cancer cells more vulnerable to treatment by blocking a pathway they use to survive DNA damage.

In early May, Zentalis advanced its strategic oncology pipeline by dosing the first patient in its global ASPENOVA Phase 3 trial to evaluate azenosertib as a monotherapy for ovarian cancer.

Later that month, the company presented promising combination data showing a 39.1 percent overall response rate. Backed by US$211.8 million in cash, Zentalis management confirmed in the firm's Q2 results that its current capital will fully fund operations and clinical milestones into late 2027.

4. Fate Therapeutics (NASDAQ:FATE)

Year-to-date gain: 213.41 percent
Market cap: US$362.5 million
Share price: US$3.11

Fate Therapeutics is a cell therapy company creating immune cells from induced pluripotent stem cells, or iPSCs.

According to the company, the idea is to create standardized cell therapies for cancer and autoimmune disease instead of manufacturing a custom treatment for each patient.

The US Food and Drug Administration recently cleared Fate's investigational new drug application for FT839, a CAR-T therapy designed to hunt down and eliminate the malfunctioning B-cells responsible for severe autoimmune diseases. This will allow the company to launch a Phase 1/2 basket trial in the second half of 2026.

5. TuHURA Biosciences (NASDAQ:HURA)

Year-to-date gain: 203.9 percent
Market cap: US$149.02 million
Share price: US$2.34

TuHURA Biosciences is a cancer immunotherapy company developing therapies that help the immune system attack tumors that have not responded to other treatments.

Its strategy is to combine or develop drugs that overcome resistance to checkpoint inhibitors, including IFx-2.0 for Merkel cell carcinoma, and TBS-2025, a VISTA-blocking antibody for acute myeloid leukemia.

In June, TuHURA filed an investigational new drug application for the evaluation of TBS-2025 VISTA.

TuHURA executed a creative, non-equity financing strategy on April 21, entering into a US$50 million revolving credit facility backed by its largest shareholder. Combined with its existing cash, management confirmed this facility fully extends the company's operational cash runway into 2028.